Competition Increases Between Novartis, Lilly & Pfizer For Approval Of New Breast Cancer Drug
March 20, 2017 at 13:38 PM EDT
Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.
